Author

A. Nilsen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 2 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Research Focus:benchmarking· 1 Organism:human· 1 Approach:mechanistic / dynamical model· 1 Organism:plant (other)· 1

Frequent Co-Authors

M. K. Riscoe· 4 shared S. Pou· 4 shared R. W. Winter· 3 shared I. Bruzual· 2 shared J. S. Doggett· 2 shared R. Dodean· 2 shared A. B. Vaidya· 1 shared A. Chattopadhyay Pal· 1 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

M. K. Riscoe

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Deaza-modification of MR1 ligands modulates recognition by MR1-restricted T cells

H. Jin, N. A. Ladd, A. M. Peev, G. M. Swarbrick, M. Cansler, M. Null, C. T. Boughter, C. McMurtrey, A. Nilsen, K. M. Dobos, W. H. Hildebrand, D. A. Lewinsohn, E. J. Adams, D. M. Lewinsohn, M. Harriff

This study modifies MR1 ligands to assess their impact on MR1-restricted T cell activation, revealing variable IFN-gamma responses and structural dynamics influencing recognition.

bioRxiv · May 11, 2022Immunology

Effective Therapy Targeting Cytochrome bc1 Prevents Babesia Erythrocytic Development and Protects from Lethal Infection

J. E. Chiu, I. Renard, A. Chattopadhyay Pal, P. Singh, P. Vydyam, J. Thekkiniath, M. Kumar, S. Gihaz, S. Pou, R. W. Winter, R. Dodean, A. Nilsen, M. K. Riscoe, J. S. Doggett, C. Ben Mamoun

This study identifies an effective ELQ prodrug that prevents Babesia erythrocytic development and protects against lethal infection in mouse models.

bioRxiv · Mar 31, 2021Microbiology

Orally Bioavailable Endochin-like Quinolone Carbonate Ester Prodrug Reduces Toxoplasma gondii Brain Cysts

J. S. Doggett, T. L. Schultz, A. Miller, I. Bruzual, S. Pou, R. W. Winter, R. Dodean, L. N. Zakharov, A. Nilsen, M. K. Riscoe, V. B. Carruthers

This study develops an orally bioavailable prodrug of ELQ-316 that enhances its plasma concentrations and efficacy against Toxoplasma gondii infection.

bioRxiv · Mar 19, 2020Pharmacology & Toxicology

ELQ-331 as a prototype for extremely durable chemoprotection against malaria

M. J. Smilkstein, S. Pou, A. Krollenbrock, L. A. Bleyle, R. A. Dodean, L. Frueh, D. J. Hinrichs, Y. Li, T. Martinson, M. Y. Munar, R. W. Winter, I. Bruzual, S. Whiteside, A. Nilsen, D. R. Koop, , M. K. Riscoe

This paper evaluates ELQ-331 as a long-acting injectable chemoprotective agent against malaria, showing it provides durable protection in mice for up to 4.5 months.

bioRxiv · Jul 2, 2019Pharmacology & Toxicology

Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum is dispensable and not the functional target of putative NDH2 quinolone inhibitors

H. Ke, S. M. Ganesan, S. Dass, J. M. Morrisey, S. Pou, A. Nilsen, M. K. Riscoe, M. W. Mather, A. B. Vaidya

This paper shows that PfNDH2 in Plasmodium falciparum is not essential and that purported NDH2 inhibitors actually target the cytochrome bc1 complex.

bioRxiv · Oct 5, 2018Microbiology

Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity

D. Rozanov, A. Cheltsov, A. Nilsen, C. Boniface, J. Korkola, J. Gray, J. Tyner, C. E. Tognon, G. B. Mills, P. Spellman

The paper identifies key factors distinguishing non-toxic and toxic compounds targeting mitochondria in cancer therapy using SAR studies and a mathematical model.

bioRxiv · Oct 1, 2018Cancer Biology